TD Cowen analyst Ritu Baral downgraded Avidity Biosciences (RNA) to Hold from Buy with a price target of $74, down from $78, after the company entered into a merger agreement with Novartis (NVS) for $72 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Hold Rating Issued Amid Avidity Biosciences Acquisition and Strategic Restructuring
- Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls
- Avidity Biosciences downgraded to Neutral from Buy at Citi
- Avidity Biosciences downgraded to Neutral from Buy at Chardan
- Avidity Biosciences downgraded to Sector Perform from Outperform at RBC Capital